Clinical Trials Logo
  1. Home
  2. MDS
  3. NCT04901416

Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS

MDS Clinical Trial

Official title:
An Open-Label Pilot Study to Evaluate the Safety and Efficacy of DVX201 NK Cells in Patients With Relapsed or Refractory AML or High Risk MDS or High Risk Overlapping Myelodysplastic / Myeloproliferative Neoplasms

Clinical Trial Summary

This study involves the use of an investigational cell therapy known as DVX201. DVX201 is an investigational cell therapy that contains a type of white blood cell called natural killer (NK) cells. NK cells are a normal part of your immune system and have a lifespan of only about two weeks. They are called natural killer cells because they have the natural ability to identify and kill cells in the body that are abnormal, like cancer cells or virally infected cells. But fighting cancer can also lead to exhaustion and abnormal function of NK cells. It can also result in a significant decrease in the number of NK cells in the blood, making it more difficult for the immune system to control the disease. We believe that infusion of healthy, functional NK cells into patients with AML or MDS may boost the immune system and help by killing cancer cells that remain after chemotherapy. DVX201 is an investigational NK cell therapy that may provide a rapid and temporary source of healthy NK cells that are better able to fight those cancer cells.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04901416
Study type Interventional
Source Coeptis Therapeutics
Contact Colleen Delaney, MD
Phone +1 206-519-5304
Email colleen.delaney@coeptistx.com
Status Recruiting
Phase Phase 1
Start date December 15, 2021
Completion date July 1, 2024
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04623944 - NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS Phase 1
Recruiting NCT03680677 - Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Recruiting NCT05009537 - Optical Genome Mapping in Hematological Malignancies
Not yet recruiting NCT04110925 - Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia N/A
Terminated NCT04638309 - APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) Phase 1
Completed NCT03466320 - DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 Phase 1/Phase 2
Withdrawn NCT03138395 - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML N/A
Completed NCT04443751 - A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Phase 1
Completed NCT02103478 - Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) Phase 1/Phase 2
Completed NCT00863148 - Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Phase 2
Completed NCT00761449 - Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 Phase 2
Completed NCT00692926 - Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells Phase 1
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A
Completed NCT02214407 - Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Phase 3
Recruiting NCT05582902 - Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
Not yet recruiting NCT05024877 - Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia Phase 2/Phase 3
Completed NCT00321711 - Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents Phase 2
Recruiting NCT06156579 - Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML Phase 2
Recruiting NCT05226455 - Venetoclax in Patients With MDS or AML in Relapse After AHSCT Phase 1/Phase 2
Completed NCT01690507 - Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） Phase 1/Phase 2